// App-Quantinova.ai

: Until what age should we worry about inhibitors? New data from the PedNet Registry on 1,038 PUPs with severe hemophilia a followed from the first until over 1,000 exposure days

Researchers

Presenter

  • M. van den Berg

Principal Investigators

  • R. Ljung

  • C. Male

  • G. Kenet

  • M. Carcao

  • H. Chambost

  • K. Fischer

  • J. Oldenburg

  • M. T. Alvarez Romn

  • E. Santagostino

  • C. Knigs

  • M. Williams

  • R. Liesner

  • A. Santamaria Ortiz

  • M. Bhrlen

  • N. Gretenkort Andersson

  • M. Carvalho

  • A. Mkipernaa

  • E. Chalmers

  • A. C. Molinari

  • B. Nolan

  • A. R. Cid

  • S. Claeyssens

  • H. Platokouki

  • A. Rafowicz

  • C. Escuriola

  • S. Ranta

  • G. Rivard

  • H. Glosli

  • T. Stamm Mikkelsen

  • R. Kobelt

  • C. Van Geet

Medical Centers

  • PedNet Haemophilia Research Foundation, Baarn, Netherlands

  • Dr. v. Haunersches Kinderspital – University of Munich, Munich, Germany

  • Department of Pediatrics, Skane University Hospital, Lund, Sweden

  • Department of Urology, Medical University Vienna, Vienna, Austria

  • The National Hemophilia Center, Ministry of Health Sheba Medical Center, Tel Hashomer, Israel

  • Division of Haematology Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

  • Service d'Hématologie Pédiatrique, CHU Timone, Marseille, France

  • Hematology and Van Creveld Cinic, University Medical Center Utrecht, Utrecht, Netherlands

  • Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Bonn, Germany

  • Unidad de Coagulopatías, Hospital Universitario La Paz, Madrid, Spain

  • A. Bianchi Bonomi Hemophilia and Thrombosis Centre – Institute of Internal Medicine, IRCCS Ospedale Maggiore, Milan, Italy

  • Clinical and Molecular Hemostasis – Department of Pediatrics, University Hospital Frankfrut & Goethe University, Frankfurt am Main, Germany

  • Department of Haematology, Birmingham Children's Hospital NHS Trust, Birmingham

  • Haematology, Great Ormond Street Childrens Hospital, London, United Kingdom

  • Unitat Hemofilia, Hospital Vall d'Hebron, Barcelona, Spain

  • Klinik Bremen‐Mitte, Prof.‐Hess‐Kinderklinik, Bremen, Germany

  • Immunohemotherapy, Centro Hospitalar Sao Joao, Porto, Portugal

  • Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland

  • Paediatric Oncology, Royal Hospital for Sick Children, Glasgow, United Kingdom

  • Gaslini Hospital, Genova, Italy

  • Dept of Paediatric Haematology, Our Lady's Children's Hospital for Sick Children, Dublin, Ireland

  • Unidad de Coagulopatías, Hospital Universitario La Paz, Madrid, Spain

  • CHU Purpan Centre de traitement des hémophiles, Toulouse, France

  • Haemophilia‐Haemostasis Unit, St. Sophia Children's Hospital, Athens, Greece

  • Service Hématologique, CRTH Bicetre, Paris – Le Kremlin Bicetre, France

  • Haemophilie Zentrum Rhein Main, Morfelden-Walldorf, Germany

  • Department of Pediatrics – Clinic of Coag. Disorders, Karolinska Hospital, Stockholm, Sweden

  • Division of Hematology/Oncology, Hopital St Justine, Montréal, Canada

  • Oslo University Hospital, Oslo, Norway

  • Department of Pediactrics, Arhus Kommunehospital Skejby Sygehus, Arhus, Denmark

  • Hämophiliezentrum, Wabern, Switzerland

  • Service of Pediatric Haematology, University Hospital Leuven, Leuven, Belgium

Locations

  • Netherlands

  • Germany

  • Sweden

  • Austria

  • Israel

  • Canada

  • France

  • Spain

  • Italy

  • United Kingdom

  • Portugal

  • Finland

  • Ireland

  • Greece

  • Norway

  • Denmark

  • Switzerland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved